Three new US patents issued to the PDX Pharma’s portfolio

To date, we have had a total of 38 patent applications, and 3 patents were issued in the past 3 months. All thanks to our dedicated team of researchers.

-Patent No. 11,235,058, Immunotherapeutic constructs and methods of their use, February 1, 2022

-Patent No. 11,224,573, Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor, January 18, 2022

-Patent No. 11,207,428, Cross-linked polymer modified nanoparticles, December 28, 2021

They are the joint inventions of PDX Pharmaceuticals and OHSU. Huge thanks to our research teams, Tanya Harding of Lee & Hayes (our patent attorney), and the NIH’s NCI for sponsoring the research (R44CA217534, R44CA265751, and R44CA265752). The content is solely the responsibility of the inventors and does not necessarily represent the official views of the National Institutes of Health.